ORIGYN-FOUNDATION
ORIGYN Foundation, the Swiss non-profit foundation dedicated to identifying, authenticating and unlocking the powers of ownership for objects of value, has announced a partnership with UEFA Foundation for Children. ORIGYN and the UEFA Foundation for Children will partner to create a unique selection of collectibles and NFTs that directly benefits the foundation’s mission to fund children’s rights in areas such as health, education and integration.
As a key component of ORIGYN’s ‘NFTs for Good’ initiative, ORIGYN and UEFA Foundation for Children will create a limited collection of physical collectibles. A corresponding digital twin will be created for each of the one-of-a-kind memorabilia, including one of the toss coins that helped determine the outcome of the UEFA EURO 2020 Final between England and Italy.
“We are thrilled to partner with ORIGYN to bring these important items to the world stage and for the benefit of The UEFA Foundation for Children,” said Urs Kluser, General Secretary for the UEFA Foundation for Children. “We share a united vision of leveraging next-generation technology such as NFTs to raise money for children and world citizens across the globe. There is no better collective mission.”
ORIGYN is the only platform that ties the digital certificate to the world’s most valuable physical artifacts and collectibles. These digital twins are non-fungible, unique and, in many cases, tied to a corresponding physical object. The iconic coin will be minted by ORIGYN into a digital twin NFT and auctioned off together with the physical coin in the second quarter of 2022, alongside other rare collectibles from the foundation.
“We’re incredibly fortunate to have partnered with a foundation that shares a passion for helping children around the world. NFTs are a global technology and should benefit all,” said Daniel Haudenschild , CEO of ORIGYN Enterprise.
This series of unique sports collectibles from the UEFA Foundation for Children, as well as their corresponding digital twin NFTs, will exclusively appear on the ORIGYN-powered consumer marketplace, Impossible Things. Impossible Things will allow collectors to buy, sell and experience unique and authenticated collectibles.
The Impossible Things marketplace will launch in Q2 of 2022 with an Impossible Pass, providing holders priority access to all of the limited collection drops to appear on the marketplace.
“Leveraging ORIGYN’s proprietary technology and the unique consumer-friendly platform at Impossible Things enables us to support causes like The UEFA Foundation for Children, as well as collectors and investors who demand authenticity from the goods they purchase and the cultures that surround them,” said Tom Flanagan, Managing Director of ORIGYN Collectibles.
About the ORIGYN Foundation:
The Swiss non-profit foundation ORIGYN uses intelligent technologies, including computer vision and artificial intelligence, on decentralized computing to identify, authenticate and unlock the powers of ownership for objects of value. As the first digital certification platform built on the Internet Computer (IC), ORIGYN and its verticals generate new forms of value for some of the largest consumer asset classes in the world, including art, collectibles, digital media and luxury goods. Founded in Neuchâtel, Switzerland in October of 2020, ORIGYN operates globally in major technology and blockchain hubs around the world. The foundation’s utility token, OGY, is set to become publicly tradable in the second quarter of 2022. For more information, visit origyn.ch .
ORIGYN Foundation: Website Twitter Telegram LinkedIn Facebook Medium Instagram
For more information about Impossible Things, visit here .
About The UEFA Foundation for Children:
The UEFA Foundation for Children aims to help children and defend their rights, for example through sport and football. It provides support in the areas of health, education, access to sport, personal development, integration of minorities and employability. The Foundation, a public utility body under Swiss law, was created and started its activities on April 24, 2015. The foundation currently invests in 180 projects and has so far funded more than 400 projects in 130 countries worldwide. More than 1.8 million children have already benefited from the foundation's work since its creation.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220422005488/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Deciphera Announces Oral Presentation of Positive Topline Results from Phase 2a Study of Sapablursen in Polycythemia Vera at the 67th American Society of Hematology (ASH) Annual Meeting6.12.2025 15:30:00 CET | Press release
Results from Phase 2a IMPRSSION study demonstrate sapablursen significantly reduced phlebotomy rate, controlled hematocrit and increased serum hepcidin Sapablursen was generally safe and well tolerated Results support further development of sapablursen in a Phase 3 study Deciphera Pharmaceuticals, a member of Ono Pharmaceutical Co., Ltd. (Headquarters: Osaka, Japan; President and COO: Toichi Takino; “Ono”), today announced the oral presentation of positive results from the Phase 2a IMPRSSION study of sapablursen in patients with polycythemia vera (PV) at the 67th American Society of Hematology (ASH) Annual Meeting, taking place December 6-9, 2025, in Orlando, FL. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251206361611/en/ The results were presented by Ionis Pharmaceuticals, who discovered and developed sapablursen and conducted the IMPRSSION study. In March 2025, Ionis and Ono entered into a license agreement in which On
Protagonist and Takeda Present Longer-Term Data at ASH 2025 Showing Rusfertide Delivers Durable Response and Hematocrit Control in Polycythemia Vera6.12.2025 15:30:00 CET | Press release
52-Week Results from the Phase 3 VERIFY Study of Rusfertide Demonstrated Sustained Hematocrit Control and Response, Defined by Absence of Phlebotomy Eligibility, with No New Safety SignalsThese Data Build on Positive 32-Week Primary Analysis from VERIFY, Which Met its Primary Efficacy Endpoint and All Four Key Secondary EndpointsPatients Crossing Over from Placebo to Rusfertide at 32 Weeks Achieved a Similar Response Rate to Those Initially Randomized to Rusfertide, with 77.9% Achieving Absence of Phlebotomy Eligibility Between Weeks 40-52Four-Year Results from the Combined REVIVE and Long-Term Extension THRIVE Study Demonstrated a 13-Fold Reduction in Annual Rate of Phlebotomies from Baseline Protagonist Therapeutics, Inc. (“Protagonist”) (NASDAQ:PTGX) and Takeda (TSE:4502/NYSE:TAK) announce that new 52-week results from the pivotal Phase 3 VERIFY study evaluating rusfertide in patients with polycythemia vera (PV) will be presented in an oral presentation at the 67th American Society
Vertex Presents New Data on CASGEVY®, Including First-Ever Data in Children Ages 5-11 Years, at the American Society of Hematology Annual Meeting and Announces Plan for Global Regulatory Submissions6.12.2025 13:01:00 CET | Press release
- Data from pivotal studies of CASGEVY in children ages 5-11 years with severe sickle cell disease or transfusion-dependent beta thalassemia demonstrates the transformative potential of the therapy in younger patients -- Efficacy and safety data in children 5-11 years are consistent with the durable and positive benefit/risk profile established from clinical studies in patients 12 years of age and older -- Vertex expects to initiate global regulatory submissions for CASGEVY in children 5-11 years in 1H 2026 - Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced data from multiple studies demonstrating the clinical benefits of CASGEVY® (exagamglogene autotemcel) in people ages 5 years and older living with severe sickle cell disease (SCD) or transfusion-dependent beta thalassemia (TDT). The results, including the first presentation of clinical data from pivotal studies in children ages 5-11 years, and longer-term data from the pivotal studies of people with severe SCD and
Leading Global Scientists Gather at Tengchong Scientists Forum to Explore Innovative Pathways in Frontier Technologies6.12.2025 12:31:00 CET | Press release
The 2025 Tengchong Scientists Forum opened on Saturday in southwest China’s Yunnan Province, convening leading scientists and academic figures to examine innovation across frontier fields including artificial intelligence, biodiversity and quantum technology. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251205499197/en/ Opening ceremony of Tengchong Scientists Forum on 6th December, 2025 Notable participants include Nobel Physics laureate Konstantin Novoselov, Fields Medalist Efim Zelmanov and Turing Award winner Andrew Chi-Chih Yao, who join 127 academicians, 77 university presidents from China and abroad, over 400 scholars and more than 600 entrepreneurs and financiers. The gathering aims to deepen collaboration between cutting-edge research and industrial development. Under the theme “Science · AI changing the World,” the forum features ten sub-forums, academic sessions and thematic events supporting major cooperation p
Lattice Wins 2025 Global Semiconductor Alliance Award6.12.2025 00:49:00 CET | Press release
‒ Named Most Respected Public Semiconductor Company Achieving $100 Million to $500 Million in Annual Sales ‒ Lattice Semiconductor (NASDAQ: LSCC), the low power programmable leader, today announced that it was selected as ‘Most Respected Public Semiconductor Company’ at the 2025 Global Semiconductor Alliance (GSA) Awards. The GSA awards recognize companies that have demonstrated excellence through their success, vision, strategy, and future opportunities in the industry as determined by votes from GSA members. “We are honored to be recognized by the Global Semiconductor Alliance and our peers as one of 2025’s most respected public semiconductor companies. This recognition reflects the dedication of the Lattice team and the trust of our customers, partners, suppliers, and investors. Looking ahead, we remain laser-focused on driving innovation and strengthening our role as the trusted low power programmable leader for semiconductor and system solutions,” said Ford Tamer, Chief Executive
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom